|
시장보고서
상품코드
2064714
위식도 역류질환(GERD) 치료제 시장 규모, 점유율 및 성장 분석 : 약제 클래스별, 질환 유형별, 투여 경로별, 유통 채널별, 최종사용자별, 환자 그룹별, 지역별 - 업계 예측(2026-2033년)Gastroesophageal Reflux Disease Therapeutics Market Size, Share, and Growth Analysis, By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel, By End User, By Patient Group, By Region - Industry Forecast 2026-2033 |
||||||
세계의 위식도 역류질환(GERD) 치료제 시장 규모는 2024년에 67억 달러로 평가되었고, 2025년 69억 5,000만 달러에서 2033년까지 93억 7,000만 달러로 확대되어 예측 기간(2026-2033년)에 CAGR 3.8%를 기록할 것으로 예측됩니다.
위식도 역류 질환(GERD) 치료제 시장은 GERD 유병률 증가와 진단 접근성 향상에 힘입어 눈부신 성장을 이루고 있으며, 그 결과 효과적인 치료법에 대한 지속적인 수요가 발생하고 있습니다. 이 시장에는 산 분비를 억제하는 처방약, 증상을 완화하는 일반의약품, 외과적 및 내시경적 시술, 그리고 첨단 진단 도구 등 다양한 치료법이 포함됩니다. GERD 치료에 따른 경제적 부담은 막대하지만, 양성자 펌프 억제제(PPI), 특히 오메프라졸에 대한 의존도가 높아지는 한편, 칼륨 경쟁형 산 분비 억제제나 내시경적 펀도플리케이션과 같은 비침습적 치료법의 도입이 확대되고 있는 뚜렷한 추세가 나타나고 있습니다. 치료 전략의 진화는 연구개발(R&D) 투자 확대 및 진단 능력 향상과 맞물려, 기존의 PPI 요법에 내성을 보이는 환자들의 미충족 의료 수요에 대응하는 방향으로의 전환을 반영하고 있습니다.
세계 위식도 역류질환(GERD) 치료제 시장의 성장 요인
위식도 역류 질환(GERD)의 유병률 증가가 효과적인 치료법에 대한 수요 증가를 이끌고 있습니다. GERD 증상 완화를 원하는 사람들이 늘어남에 따라, 의료 종사자와 의료 시스템은 치료 경로 개선에 점점 더 적극적인 태도를 보이고 있으며, 이는 제약 기업의 혁신과 새로운 치료법 개발을 촉진하고 있습니다. 환자들의 증상에 대한 인식이 높아지고, 이 질환이 초래하는 지속적인 부담이 맞물리면서 처방된 치료에 대한 높은 순응도가 촉진되고 있습니다. 이러한 추세는 치료 시장의 확대로 이어질 뿐만 아니라, 1차 진료 현장에서 GERD 관리의 통합을 더욱 촉진하여, 결과적으로 제품 사용 확대와 시장 성장을 뒷받침하고 있습니다.
세계 위식도 역류질환(GERD) 치료제 시장의 제약 요인
세계 위식도 역류병 치료제 시장은 표준 치료제에 비해 새로운 치료법이나 투여 시스템의 가격 상승으로 인해, 환자들의 접근성과 보험 적용 범위 임베디드이 제한된다는 큰 제약에 직면해 있습니다. 의료 예산이逼迫하는 가운데, 공적 및 민간 보험사들은 저비용 대체 요법과 비교했을 때 이러한 혁신적인 치료법이 가져다주는 추가적인 이점을 점점 더 엄격하게 검토하고 있으며, 그 결과 사전 승인이나 단계적 보상 등 보다 엄격한 접근 조치가 취해지는 경우가 늘고 있습니다. 게다가, 보험 적용 범위의 제한이나 높은 본인 부담금으로 인해 경제적 부담이 우려되어, 치료의 시작과 지속 모두에 차질이 생기고 있습니다. 이러한 상황은 시장 진출을 현저히 지연시키고, 새로운 치료법의 신속한 상용화에 대한 의지를 약화시키고 있습니다.
세계 위식도 역류 질환(GERD) 치료제 시장 동향
세계 위식도 역류 질환(GERD) 치료제 시장에서는 개별 환자의 고유한 요구에 부응하는 맞춤형 치료 방식으로의 전환이 점점 더 두드러지고 있습니다. 임상의와 개발자들은 표현형, 증상 양상, 동반 질환 등 다양한 요인을 고려하여 환자에게 맞춘 관리 전략을 우선시하고 있습니다. 이러한 동향은 치료 방침을 결정하고, 표적에 맞춘 약물 선택을 용이하게 하며, 불필요한 치료를 최소화하기 위한 조치를 개별화하기 위해 바이오마커의 활용을 중시하는 것입니다. 적응형 임상 경로(adaptive clinical pathways)의 구축과 환자와의 공동 의사결정(shared decision-making) 촉진을 통해, 시장은 환자의 삶의 질(QOL)과 치료 성과를 종합적으로 향상시키는 의료적, 행동적, 그리고 생활습관과 관련된 종합적인 중재를 통합하는 방향으로 진화하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 위식도 역류질환(GERD) 치료제 시장 규모 : 약제 클래스별
세계의 위식도 역류질환(GERD) 치료제 시장 규모 : 질환 유형별
세계의 위식도 역류질환(GERD) 치료제 시장 규모 : 투여 경로별
세계의 위식도 역류질환(GERD) 치료제 시장 규모 : 유통 채널별
세계의 위식도 역류질환(GERD) 치료제 시장 규모 : 최종사용자별
세계의 위식도 역류질환(GERD) 치료제 시장 규모 : 환자 그룹별
세계의 위식도 역류질환(GERD) 치료제 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
LSH 26.06.29Global Gastroesophageal Reflux Disease Therapeutics Market size was valued at USD 6.70 Billion in 2024 and is poised to grow from USD 6.95 Billion in 2025 to USD 9.37 Billion by 2033, growing at a CAGR of 3.8% during the forecast period (2026-2033).
The gastroesophageal reflux disease (GERD) therapeutics market is experiencing significant growth fueled by rising GERD prevalence and enhanced diagnostic accessibility, thus creating a continuous demand for effective treatments. This market encompasses a range of therapies, including prescription medications that inhibit acid secretion, over-the-counter remedies that alleviate symptoms, surgical and endoscopic interventions, and advanced diagnostic tools. Though the economic burden of GERD treatment is substantial, there is a notable trend toward increased reliance on proton pump inhibitors (PPIs), particularly omeprazole, while introducing potassium competitive acid blockers and less invasive options like endoscopic fundoplication. The evolution in treatment strategies, coupled with heightened R&D investments and improved diagnostic capabilities, reflects a shift towards addressing the unmet needs of patients resistant to traditional PPI therapies.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastroesophageal Reflux Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Gastroesophageal Reflux Disease Therapeutics Market Segments Analysis
Global gastroesophageal reflux disease therapeutics market is segmented by drug class, disease type, route of administration, distribution channel, end user, patient group and region. Based on drug class, the market is segmented into proton pump inhibitors (PPIs), H2 receptor antagonists, antacids, prokinetic agents, potassium-competitive acid blockers (P-CABs) and others. Based on disease type, the market is segmented into erosive GERD, non-erosive reflux disease (NERD), refractory GERD and GERD with Barrett's esophagus. Based on route of administration, the market is segmented into oral and injectable. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, specialty clinics and homecare settings. Based on patient group, the market is segmented into pediatric, adult and geriatric. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Gastroesophageal Reflux Disease Therapeutics Market
The rising incidence of gastroesophageal reflux disease (GERD) is driving an escalating demand for effective treatments. As more individuals seek relief from GERD symptoms, healthcare providers and systems are increasingly motivated to enhance treatment pathways, which in turn encourages pharmaceutical companies to innovate and develop new therapeutic options. Patients' growing awareness of their symptoms, coupled with the persistent burden of the condition, fosters high adherence to prescribed therapies. This dynamic not only expands the treatment market but also facilitates deeper integration of GERD management within primary care settings, thereby boosting overall product utilization and market growth.
Restraints in the Global Gastroesophageal Reflux Disease Therapeutics Market
The Global Gastroesophageal Reflux Disease Therapeutics market faces significant restraints due to the high pricing of new therapies and delivery systems compared to standard medications, which restricts patient access and formulary inclusion. As healthcare budgets tighten, public and private payers increasingly scrutinize the incremental benefits of these innovative treatments against lower-cost alternatives, often leading to stricter access measures such as prior authorization or tiered reimbursement. Additionally, limited insurance coverage and high out-of-pocket costs raise affordability concerns, hindering both the initiation and continuation of treatment. This situation significantly slows market penetration and diminishes the motivation for rapid commercialization of new therapies.
Market Trends of the Global Gastroesophageal Reflux Disease Therapeutics Market
The Global Gastroesophageal Reflux Disease (GERD) Therapeutics market is increasingly witnessing a shift towards personalized treatment approaches that cater to the unique needs of individual patients. Clinicians and developers are prioritizing tailored management strategies by considering various factors such as phenotypes, symptom patterns, and comorbidities. This trend emphasizes the use of biomarkers to guide therapeutic decisions, facilitate the selection of targeted pharmacologic agents, and tailor procedural interventions to minimize unnecessary treatments. By fostering adaptive clinical pathways and promoting shared decision-making, the market is evolving to integrate comprehensive medical, behavioral, and lifestyle interventions that collectively enhance patient quality of life and treatment outcomes.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
- Value Chain Analysis
- Case Studies
- Technology Assessment
- Customer & Buying Criteria Analysis
- Pipeline Analysis
- Disease Epidemiology
Global Gastroesophageal Reflux Disease Therapeutics Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Proton Pump Inhibitors (PPIs)
- H2 Receptor Antagonists
- Antacids
- Prokinetic Agents
- Potassium-Competitive Acid Blockers (P-CABs)
- Others
Global Gastroesophageal Reflux Disease Therapeutics Market Size by Disease Type & CAGR (2026-2033)
- Market Overview
- Erosive GERD
- Non-Erosive Reflux Disease (NERD)
- Refractory GERD
- GERD with Barrett's Esophagus
Global Gastroesophageal Reflux Disease Therapeutics Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral
- Injectable
Global Gastroesophageal Reflux Disease Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Gastroesophageal Reflux Disease Therapeutics Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Clinics
- Homecare Settings
Global Gastroesophageal Reflux Disease Therapeutics Market Size by Patient Group & CAGR (2026-2033)
- Market Overview
- Pediatric
- Adult
- Geriatric
Global Gastroesophageal Reflux Disease Therapeutics Market Size & CAGR (2026-2033)
- North America (Drug Class, Disease Type, Route of Administration, Distribution Channel, End User, Patient Group)
- US
- Canada
- Europe (Drug Class, Disease Type, Route of Administration, Distribution Channel, End User, Patient Group)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Class, Disease Type, Route of Administration, Distribution Channel, End User, Patient Group)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Class, Disease Type, Route of Administration, Distribution Channel, End User, Patient Group)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Class, Disease Type, Route of Administration, Distribution Channel, End User, Patient Group)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Phathom Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eisai
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GSK
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch Health Companies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Torrent Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cadila Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Daewoong Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Yuhan Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sebela Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
